Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson

Rogers

Amgen

Bristol-Myers

Gilead Sciences

Merck

Novo Nordisk

Novartis

Pfizer

Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

The Top 10 Biotechnology Companies (JNJ, ROG.VX)

AbbVie

Bayer AG

GlaxoSmithKline

Eli Lilly

Roche Holding AG

SPDR S&P Pharmaceuticals ETF

"We're working on it right now a favored nations clause where we pay the lower nation's price is, like Canada," President Donald Trump tells reporters.

Trump says administration preparing an executive order on drug prices

Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.

Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer

Regeneron Pharmaceuticals

Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.

Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation

AstraZeneca

According to the GuruFocus All-in-One Screener, the following companies look cheap since they are trading with low price-sales ratios.

Stocks With Low Price-Sales Ratios

The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.

FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review

Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.

Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion

AnaptysBio stock tumbled Friday after the results of a study from Regeneron Pharmaceuticals and Sanofi cast doubt on the biotech company's ability to compete in asthma treatment.

Regeneron And Sanofi Tried To Outperform Themselves — And Couldn't

Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

Sanofi on Wednesday said a reorganization of its research and development operation in Germany and France would result in 466 job cuts in the two countries.

Sanofi plans 466 job cuts as part of R&D reshuffle

Alphabet

Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.

Sanofi Partners Google to Build Healthcare Innovation Lab

Sanofi (SNY) shares rose nearly 6% in the last trading session, amid huge volumes.

Sanofi (SNY) in Focus: Stock Moves 5.5% Higher

With big pharma companies grappling with fundamental as well as geopolitical issues — including aging pipelines, key blockbuster drugs going off patent and a U.S. clampdown on drug pricing — many have turned to new leadership in recent years to reinvigorate growth.

Sanofi's Leadership Transition: What You Need To Know

There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.

New Sanofi CEO 2019: 8 Things to Know About Paul Hudson

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

In veteran drug salesman Paul Hudson, Sanofi's 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

France's Sanofi bets on new CEO to drive sluggish drug sales

French pharma giant Sanofi has appointed Paul Hudson as chief executive to replace Olivier Brandicourt, who will retire in September, the company said on Friday.

Drugmaker Sanofi appoints Novartis executive Hudson as new CEO

French pharma giant Sanofi appointed Paul Hudson as chief executive to replace Olivier Brandicourt, who will retire in September, the company said on Friday.

Sanofi appoints Paul Hudson as CEO to replace retiring Brandicourt

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

Alnylam Pharmaceuticals

BioMarin Pharmaceutical

BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.

BioMarin Announces Data on Hemophilia Candidate, Shares Fall

Sanofi is a pharma company putting in very consistent performances.

Sanofi: A Robust Pharma Giant With Strong Growth In Q1

Apple

Activision Blizzard

Microsoft

Tencent Holdings Limited

If you're looking to invest in the growing popularity of video games, you might want to start by considering these sector winners.

These 6 Giants Control Half the Global Video Game Market

Amarin Corporation Plc

Cellectar BioSciences

GW Pharmaceuticals

The biotechnology space is an exciting one with incredible potential for investors.

5 Biotech Stocks With Near-Term Catalysts Ahead

Sanofi S.A. (SNY) CEO Olivier Brandicourt on Q1 2019 Results - Earnings Call Transcript

Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.

News for Sanofi Stock (SNY)